I do not think the story is getting old. I think with the share appreciation it is perfectly normal for the stock to consolidate.
The company has been steadfast that they are aiming for $50 million in 2022 revs. I believe that the Street is shifting to a "show me" mode. Will need to see some revenue and profit acceleration.
I also believe that within the next 12-18 months KRMD can have a new source of revenues that is not factored into the stock. Maybe a new partnership or an expanded label use for a sub-q drug.
I have not bought any stock back yet. Stock continues to hold but meander around the 10 week moving average - $5.56 right now.
Market Data 
Markets 
AI
